Skip to main content
. 2021 May 24;27(15):4325–4337. doi: 10.1158/1078-0432.CCR-20-3760

Figure 4.

Figure 4. Ultrasound-mediated BBBD with CAR T-cell therapy was associated with increased mouse survival durations. A, Treatment schema for NSG mice bearing EGFRvIII-expressing U87 tumors and treatment on day 14 with EGFRvIII/ffLuc CAR T cells. B, Survival of NSG mice treated with EGFRvIII-CAR T cells or EGFRvIII-CAR T cells with ultrasound. Survival was determined using Kaplan–Meier analysis with a one-tailed t test for independent samples. The MS duration in the treatment groups were as follows: EGFRvIII-CAR T-cell (four mice), 35 days; EGFRvIII-CAR T cells with ultrasound (seven mice), undefined. Statistics: EGFRvIII-CAR T cells versus EGFRvIII-CAR T cells with ultrasound, P = 0.04423.

Ultrasound-mediated BBBD with CAR T-cell therapy was associated with increased mouse survival durations. A, Treatment schema for NSG mice bearing EGFRvIII-expressing U87 tumors and treatment on day 14 with EGFRvIII/ffLuc CAR T cells. B, Survival of NSG mice treated with EGFRvIII-CAR T cells or EGFRvIII-CAR T cells with ultrasound. Survival was determined using Kaplan–Meier analysis with a one-tailed t test for independent samples. The MS duration in the treatment groups were as follows: EGFRvIII-CAR T-cell (four mice), 35 days; EGFRvIII-CAR T cells with ultrasound (seven mice), undefined. Statistics: EGFRvIII-CAR T cells versus EGFRvIII-CAR T cells with ultrasound, P = 0.04423.